Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However ...

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

We recently compiled a list of the 10 Firms End Trading Week Defying Market Bloodbath. In this article, we are going to take ...

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Did you know Robin Roberts’ openness about her health journey led to an astounding 1,800% increase in bone marrow donor ...

The top content from the Institute for Value-Based Medicine® (IVBM®) highlighted innovative approaches to improving care ...

Based Roundtable® event, Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as ...

We recently compiled a list of the 10 Biggest Losers of This Week. In this article, we are going to take a look at where ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

ABVC BioPharma, Inc. (NASDAQ:ABVC – Get Free Report) was the target of a large growth in short interest during the month of ...